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Idiotype (Id)-based immunotherapy has been exploited as cancer treatment option. Con-
ceived as therapy for malignancies bearing idiotypic antigens, it has been also extended
to solid tumors because of the capacity of anti-idiotypic antibodies to mimic Id-unrelated
antigens. In both these two settings, efforts are being made to overcome the poor immune
responsiveness often experienced when using self immunoglobulins as immunogens.
Despite bearing a unique gene combination, and thus particular epitopes, it is normally
difﬁcult to stimulate the immune response against antibody variable regions. Different
strategies are currently used to strengthen Id immunogenicity, such as concomitant use
of immune-stimulating molecules, design of Id-containing immunogenic recombinant pro-
teins, speciﬁc targeting of relevant immune cells, and genetic immunization. This review
focuses on the role of anti-Id vaccination in cancer management and on the current
developments used to foster anti-idiotypic B andT cell responses.
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Immunoglobulins (Ig) are glycoproteins formed by two identical
heavy and two identical light polypeptide chains. The N-terminal
ends of each pair of heavy-light chains consist of two variable (V)
immunoglobulin (Ig) domains (VL and VH) that form a unique
surface for antigen binding. V regions are generated during B cell
ontogeny by the so-called VDJ rearrangement of the germ-line
Ig genes. This genetic rearrangement allows for the tremendous
initial diversity of human Igs in naïve B cells, a critical feature
of the immune system, which is further increased and reshaped
by somatic hyper-mutation of V regions in antigen-stimulated
mature B cells.
The association of the two V domains generates the idiotype
(Id), a distinctive structure and a unique collection of antigenic
determinants called idiotopes. Idiotopes derive mainly from the
CDR regions of the Ig V domains, frequently found to be of
a conformational nature and derived from somatic mutations
(Figure 1). Despite being self-proteins Ids can be immunogenic.
For this reason Ids have been exploited as therapeutic immuno-
gens in cancer treatment in two well-deﬁned and clearly distinct
contexts: (i) directly as a tumor-speciﬁc target on membrane Ig-
positive malignant B cells as a consequence of their clonotypic
origin, and (ii) as surrogate of tumor-associated antigen (TAA) to
induce speciﬁc immune responses (Figure 2).
In the ﬁrst case the Id itself represents the immunogen and
the target on the surface of the malignant B cell. Because of their
clonotypic origin the Id expressed by malignant B cells repre-
sents the only true example of tumor-speciﬁc antigen (Anderson
et al., 1984). Therapeutic strategies that target the unique structure
of the Id of each malignant clone constitute therefore a pow-
erful tool for the treatment of B cell malignancies (Bendandi,
2009; Figure 2A). These strategies are essentially based on the
generation of an anti-Id antibody and/or T cell-based immune
response by means of protein or DNA-based vaccines. The success
of these approaches to eradicate established tumors or pre-
vent their development has been largely demonstrated in animal
models.
The second relevant context focuses on the use of a deﬁned Id
to induce, through a mechanism of molecular mimicry, a speciﬁc
immune response against a TAA. In this case the system entails the
selection of an anti-idiotypic antibody (Ab2) generated against the
Id of an Ab1 speciﬁc for the TAA. The Id of the Ab2 is, in turn,
used to induce an anti-idiotypic anti-Ab2 response (Ab3) that will
not only recognize the immunizing Id of Ab2, but very frequently
also the antigen for which the Ab1 is speciﬁc (Lopez-Requena and
Burrone, 2009). The Id of Ab2 is said to carry the “internal image”
of the antigen, in other words to mimic its structure, and there-
fore able to replace the latter for inducing the immune response
(Figures 2B,C).
Antigen mimicry is, however, a still not-completely understood
phenomenon. The concept is based on the idea that if both the
antigen and the Id of the Ab2 bind to the antigen-combining site
of Ab1 (paratope), then the paratope of the Ab2 would struc-
turally resemble the antigen (Figure 2B). While in some examples
structural homology between antigen and the Ab2 Id has been
demonstrated to a certain extent (Pride et al., 1992; Chatterjee
et al., 1998; Spendlove et al., 2000; Chang et al., 2005), this is hardly
the case when it comes to non-protein antigens (Talavera et al.,
2009). Nevertheless, irrespective of themolecular basis of mimicry,
the fact is that someAb2 induce antibodies that bind to the antigen.
The strategy of active immunotherapywith anti-idiotypic vaccines
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FIGURE 1 | Schematic representation of an immunoglobulin (Ig).The
idiotype (Id), constituted by the variable regions of the heavy (VH) and light
(VL) chains, is shown. CDRs are highlighted in red (VH) and blue (VL).
has been widely explored in cancer (Bhattacharya-Chatterjee et al.,
2002; Lopez-Requena and Burrone, 2009).
Thus, an Ig Id can be conceived and used as an antigen to
induce anti-Id responses in two different frameworks: (i) the Id
itself as a target antigen on tumor cells, as in the case of B cell
lymphomas (Figure 2A), and (ii) the Id as a mimic of a tumor
antigen, with the anti-Id response ultimately intended to target the
latter (Figures 2B,C). There is, however, an important distinction
between the two cases. While the Id expressed on a tumor cell is
a self-antigen, and therefore immunological tolerance is expected,
this is not the case when it is used as a mimic of another antigen. In
addition,Ab2 are frequently obtained in mice, for which the whole
Ig is a foreign antigen for the patient. The response against the Id
can thus be favored, and the constant region can act as a xeno-
geneic carrier. Nevertheless, in cases when the mouse antibody
is not highly immunogenic immune-stimulating compounds are
required to enhance the response (McCaffery et al., 1996).
Despite encouraging results at the preclinical level, Id-based
immunotherapy has given disappointing outcomes in patients.
Immunization with lymphoma Ids or anti-idiotypic antibodies
mimicking tumor antigens has been demonstrated to be feasible
and safe in clinical trials, despite proof of clinical efﬁcacy is still
awaited (deCerio et al., 2007). Aswith the latter strategy (Giaccone
et al., 2005), initial phase III clinical trials using Id vaccines in lym-
phoma patients did not meet their primary end points (Bendandi,
2009; Kannan andNeelapu, 2009; Rezvani and de Lavallade, 2011),
highlighting the need for deeper research in both, the identiﬁca-
tion of predictors of the immune response in patients (Inoges et al.,
2011a) and the design of clinical studies (Bendandi, 2009; Ino-
ges et al., 2011b). Also, the improvement of vaccination strategies
is an important issue under intense investigation (Bhattacharya-
Chatterjee et al., 2002; Hollander, 2009; Rezvani and de Lavallade,
2011). The last issue will be the focus of this review.
IMMUNE-STIMULATING CARRIERS AND ADJUVANTS
In 1975, Herman Eisen reported the ﬁrst case of induction of
active immunity to a tumoral Id in a murine plasmacytoma
model (Eisen et al., 1975). Vaccination with the idiotypic protein,
obtained and puriﬁed from plasma, was efﬁcient to protect ani-
mals against subsequent tumor challenge. However, the possibility
of establishing an anti-Id response in patients with Ig-secreting
tumors was low, and attention turned to lymphomas where tumor
cells display membrane bound Ig but secrete little. Pioneering
studies in several murine lymphoma models demonstrated that
the low immunogenicity of idiotypic protein can be efﬁciently
overcome when Id was linked to a strong immunological carrier
such as keyhole limpet hemocyanin (KLH). Using this approach,
induction of high titers of anti-Id antibodies and protection
against tumor challenge was demonstrated (Campbell et al., 1987,
1990; Kaminski et al., 1987; George et al., 1988), even in animals
with established lymphoma (Campbell et al., 1988), suggesting
that, although nominally self-antigens, idiotypic determinants
can become immunogenic when administered in a context that
allows overcoming T cell tolerance. The experience gained in
murine studies led to the ﬁrst clinical trials of patients with
low-grade, follicular lymphoma, primarily those in ﬁrst remis-
sion following chemotherapy (Kwak et al., 1992). While this study
reported the induction of an Id-speciﬁc humoral response, nei-
ther the activation of Id-speciﬁc T cells nor clinical efﬁcacy were
described. A phase II clinical study conducted by the National
Cancer Institute ﬁrst demonstrated clinical efﬁcacy upon immu-
nization with Id protein coupled to KLH and co-administered
with granulocyte-monocyte colony stimulating factor (GM-CSF).
The study described the clearance of residual tumor cells and
long-term disease-free survival in follicular lymphoma patients
in ﬁrst complete remission after standard chemotherapy (Ben-
dandi et al., 1999). The correlation between Id-speciﬁc immune
response and in vivo control of minimal residual disease was also
found in a similar study conducted in Europe (Barrios et al., 2002).
More recently, clinical beneﬁt associated to KLH-conjugated Id
vaccines in lymphoma patients was reported in small phase II
trials (Inoges et al., 2006; Redfern et al., 2006; Timmerman et al.,
2009). However, clinical phase III studies aimed at obtaining reg-
ulatory approval for Id vaccines failed to reach their primary
endpoints (Bendandi, 2009;Schuster et al., 2011a). Many factors
have been taken into account as possible predictors of vaccination
efﬁcacy and induction of a clinically relevant immune response.
In a recent double-blind multi-center controlled phase III trial in
patients with follicular lymphoma, the outcome of vaccination
with the patient-speciﬁc hybridoma-derived Id was dependent on
the tumor Ig isotype, with IgM being signiﬁcantly more effective
than IgG (Schuster et al., 2011b). Despite the existence of Ids with
an “intrinsic” ability to generate a syngeneic immune response
irrespective of the format (Lopez-Requena et al., 2007b), the IgM
isotypehas been associatedwith immunogenicity in contrast to the
IgG (Reitan andHannestad,1995,2001,2002),whichwas shown in
turn, to contain epitopes in the Fc region able to activate regula-
tory T cells (De Groot et al., 2008). With the aim of improving
vaccine efﬁcacy in patients, the possibility that Id-KLH cross-
linking with glutaraldehyde may damage critical immunogenic
epitopes, has prompted researchers to look for alternative reagents.
Murine and patient-derived human Id-KLH vaccines generated
using maleimide-based conjugation were found to be superior to
glutaraldehyde conjugation to generate anti-Id immune responses
(Kaﬁ et al., 2009).
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FIGURE 2 | (A) Idiotype (Id) of an immunoglobulin (Ig)-expressing lymphoma
cell as vaccine to induce anti-lymphoma immune response. (B) Schematic
representation of the antigen-speciﬁc antibody (Ab1), the antigen
(Ag)-mimicking anti-Ab1 anti-idiotypic antibody (Ab2), the anti-Ab2
anti-idiotypic antibody (Ab3) and their interactions. (C) Id of an Ab2 as
vaccine to induce antigen-speciﬁc immune response to solid tumors.
Conjugation to KLH has also been used in the context of
antigen-mimicking anti-idiotypic vaccines. As examples, immu-
nization of melanoma patients with themouse anti-idiotypic anti-
body MK2-23, mimicking the high molecular weight-melanoma
associated antigen (HMW-MAA), was signiﬁcantly more efﬁ-
cient in inducing anti-anti-idiotypic antibodies when conjugated
to KLH and administered in association to Bacillus Calmette-
Guérin (BCG; Mittelman et al., 1995). Similarly, the murine
anti-idiotypic antibody 3H1, which mimics a speciﬁc epitope of
carcinoembryonic antigen (CEA), when conjugated to KLH and
emulsiﬁed in Freund’s adjuvant was found to be able to induce
effective anti-CEA immune responses in animals (Saha et al.,
2006b). Finally, immunization with KLH-coupled R24, a mouse
monoclonal antibody (mAb) speciﬁc for the disialoganglioside
3 (GD3), which is over-expressed on transformed melanocytes,
induced an anti-idiotypic cascade leading to the identiﬁcation of
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an anti-anti-idiotypic mAb able to mediate cytotoxicity on human
melanoma cells and to inhibit tumor growth in xenografted mice
(Ramos et al., 2011).
Apart from KLH, GM-CSF has been extensively tested
in numerous protein immunization studies (Tao and Levy,
1993;Chen et al., 1994; Kwak et al., 1996),which altogether demon-
strated the capacity of this cytokine to improve vaccine efﬁcacy in
terms of ability to induce Id-speciﬁc responses. The immunos-
timulatory properties of GM-CSF have been recently compared
to those raised by CpG or IFN-α. This study demonstrated that
these two last compounds are better immune adjuvants as, in
contrast toGM-CSF, their administration induced efﬁcient protec-
tion in a murine myeloma model upon vaccination with Id-KLH
protein (Hong et al., 2012). Similarly, CpG co-administration sig-
niﬁcantly improved the cellular anti-CEA response in transgenic
mice expressing human CEA and vaccinated with the CEA-
mimicking murine 3H1 mAb (Ab2). In a CEA-transfected murine
colon carcinoma cell model, the vaccine was effective in induc-
ing protective anti-tumor immunity (Saha et al., 2006a). Other
cytokines that have been explored in animals, as Id-fusionproteins,
include IL-2 (Chen et al., 1994; Wang et al., 2005) and IL-4 (Chen
et al., 1994).
Alum, QS-21, and BCG are adjuvants that have been used
in the clinics in anti-idiotypic vaccine formulations with dif-
ferent antigen-mimicking murine Ab2 mAbs (Mittelman et al.,
1995; Foon et al., 1999; Birebent et al., 2003; Giaccone et al., 2005;
Grisham et al., 2011;Soriano et al., 2011). An interesting case is the
Id of 1E10mAb,whichmimics a tumor-associated type of ganglio-
side (Alfonso et al., 2002; Diaz et al., 2003; Hernandez et al., 2005)
and, when administered in patients as an anti-idiotypic vaccine
(racotumomab) in alum, induces a set of antibodies that bind the
ganglioside but not the 1E10 Id (Alfonso et al., 2002; Diaz et al.,
2003; Hernandez et al., 2008), and a ganglioside-speciﬁc cellular
response (Guthmann et al., 2006).
IMMUNOGENIC RECOMBINANT PROTEINS
Compared to hybridoma technology, the molecular rescue of the
tumoral Id from patient’s lymphoma cells is a less-time consum-
ing alternative. Reverse transcription-polymerase chain reaction
(RT-PCR) with family-based V gene primers allows identiﬁcation
and isolation of VL and VH region sequences directly from biopsy
materials. The tumor-associated idiotypic VL and VH chains can
then be cloned and assembled into different formats [single chain
Fv (scFv), Fab, or full-length Ig] for expression in mammalian,
bacteria, insect, or plant cells (Bird et al., 1988; Gurunathan et al.,
2000). As example, recombinant human and murine Id in scFv
format produced in plants, an appealing option that allows rapid
production and recovery of the recombinant protein, were found
to be highly immunogenic without the need of KHL cross-linking,
both in presence and in absence of adjuvant (McCormick et al.,
2008). scFv molecules can be also fused to immune-stimulating
molecules. A fusion protein consisting of 38C13 murine B cell
lymphoma scFv and tetanus toxin fragment C (FrC), produced
in E. coli as inclusion bodies or using a cell-free protein synthe-
sis system, induced anti-Id antibodies and was as effective as the
IgM-KLH Id protein in increasing survival after tumor challenge
(Patel et al., 2011).
Up to now, the only recombinant fragment assayed in the
clinics in B cell lymphoma patients is the tumor Fab-Id pro-
duced in E. coli (Bertinetti et al., 2006; Navarrete et al., 2011).
In the case of an antigen-mimicking Ab2, the F(ab′)2 fragment
from rat BR3E4 mAb, which mimics the colorectal carcinoma-
associated epitopeCO17-1A,was administered to patients coupled
to KLH and showed to bemore effective than the whole uncoupled
IgG in inducing humoral and cellular responses (Birebent et al.,
2001, 2003).
Chimeric antibodies have been assayed at the preclinical level
to increase Id immunogenicity. The 1E10 mAb expressed as a
chimeric mouse-human IgG1 and administered to mice in PBS
alone, was immunogenic in syngeneic mice and the induced
anti-idiotypic antibody response was dominant over the anti-
xenogeneic human constant region response (Lopez-Requena
et al., 2003). In contrast, chimeric antibodies containing the 38C13
murine B cell lymphoma Id required coupling toKLH for inducing
an anti-Id antibody response. However, when fused to GM-CSF,
IL-2, or IL-4, these recombinant molecules elicited anti-tumor
immunity when administered without carrier or adjuvant (Tao
and Levy, 1993; Chen et al., 1994). Similarly, a fusion protein
consisting of the HMW-MAA-mimicking chimeric MK2-23 Ab2
mAb linked to IL-2 was effective in enhancing immunogenicity
without the need of coupling to KLH (Wang et al., 2005). Recom-
binant molecules containing a single xenogeneic IgG domain
have also been designed for Id immunization. A bivalent Id pro-
tein, obtained by fusing the BCL1 murine B cell lymphoma scFv
to the CH3 domain from human IgG1 as dimerizing unit (Li
et al., 1997), was effective in inducing anti-Id antibodies when
administered either with or without adjuvant (Benvenuti and
Burrone, 2001).
DNA VACCINES
Compared with Id protein vaccines, direct vaccination with DNA
encoding the lymphoma Id is logistically easier to use and cheaper
to manufacture. In principle, it can provide longer antigen expres-
sion to enable a sustained stimulation of both humoral and T
cell-mediated immunity (Benvenuti and Burrone, 2002). As in the
case of the Id protein, initial DNA vaccination studies in murine
models showed that the tumor-derived V regions alone are poorly
immunogenic, but the relatively easy manipulation of the antigen-
encoding cassette has facilitated the testing of several different
designs to augment immunogenicity. This has been achieved by
genetically linking the Id sequence to a cytokine sequence such as
GM-CSF (Syrengelas et al., 1996) or to different CD4+ T cell epi-
tope carriers. King et al. (1998) tested plasmid-encoded Id (scFv)
as a vaccine in themurineA31Bcell lymphomaand5T33myeloma
models. Initially, only low anti-Id antibody levels and poor tumor
protection were achieved when the Id was used alone. However,
when the scFv gene was genetically linked to the FrC of tetanus
toxin, the majority of the animals tested were protected with sig-
niﬁcant enhancement of the anti-Id antibody response. Another
bacterial molecule, the B subunit of E. coli heat labile toxin, when
fused to the BCL1 murine B cell lymphoma scFv and adminis-
tered as intra-muscular injection of plasmid DNA followed by
electroporation increased the antibody response against the Id
and promoted survival in mice challenged with the tumor. These
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effects depended on the pentamerization of the fusion protein
and its binding to the GM1 ganglioside (Chen et al., 2009). On the
same line, in the 38C13murineB cell lymphomamodel, Syrengelas
et al. (1996) showed that provision of a DNA construct encoding
a constant region of human Ig linked to the Id gene was required
for speciﬁc induction of anti-Id antibodies. Moreover, vaccination
with an Id-GM-CSF fusion construct resulted in enhancement of
both anti-Id antibody levels and tumor protection. The scFv-Id
gene was also fused to a DNA encoding an immuno-enhancing
peptide derived from IL-1β and demonstrated induction of tumor
immunity that protectedmice from tumor challenge (Hakim et al.,
1996). An alternative fusion gene between a scFv and a protein
derived from a plant virus was described as a further way to pro-
vide T cell epitopes and induce protective immunity in lymphoma
and myeloma (Savelyeva et al., 2001).
Although scFv is a popular format for the design of recom-
binant Id-based vaccines (King et al., 1998), dimeric proteins
are frequently constructed by fusing the scFv with a dimeriz-
ing unit (Benvenuti et al., 2000; Fredriksen et al., 2006). In fact,
bivalency was reported to be important for efﬁcient anti-Id anti-
body induction and T cell activation by a scFv-based vaccine
(Fredriksen and Bogen, 2007). In the BCL1 model the fusion
of the scFv to the xenogeneic CH3 domain from human IgG1
was found to efﬁciently induce anti-Id antibodies and protec-
tion upon tumor challenge (Benvenuti et al., 2000). The minimal
immunizing unit that has been assayed is the heavy chain CDR3
(H-CDR3). A vaccine based on Id H-CDR3 fused to tetanus toxin
FrC was protective in the 38C13 murine B cell lymphoma model
(Iurescia et al., 2010).
One particularity of DNA vaccination is that the immunizing
molecule is per se immunostimulatory. The non-immunogenic
1E10 mAb Id, in the context of a fusion protein with CH3 domain
from mouse IgG1 (i.e., with no xenogeneic carrier), induced a
clear anti-idiotypic response by gene gun DNA immunization.
The adjuvant properties of bacterial DNA seemed to be responsi-
ble for this outcome, as when the same recombinant construct
was administered through recombinant adeno-associated virus
(rAAV) infection no response at all was detected (Lopez-Requena
et al., 2007a). In a contrasting result, the xenogeneic human IgG3
hinge/CH3 were required for good antibody responses and tumor
protection in the murine MOPC315 myeloma and A20 B cell
lymphoma models, with a DNA vaccine encoding the respective
dimeric scFv-Id fused to the MIP-1α chemokine, administered
by intramuscular injection followed by electroporation. When
the syngeneic counterparts were used, the vaccine failed to elicit
protective immunity (Fredriksen and Bogen, 2007).
VIRAL VECTORS
Administration of naked DNA has the disadvantage that a large
amount of the immunogen is degraded before entering the cells
(Dupuis et al., 2000). The use of virus-based vectors can partially
circumvent this problem allowing the efﬁcient penetration of cells
while mimicking natural infection (Chen et al., 1996). Concern-
ing the employment of viral vectors as vehicle to Id delivery in
vivo, preclinical studies were performed in two murine B cell
lymphoma models (38C13 and BCL1) to address the vaccine efﬁ-
cacy of Id-encoding adenoviruses (Timmerman et al., 2001). It
was demonstrated in both models that a single injection of Id-
adenovirus providedprotection fromsubsequent tumor challenge,
which was equivalent, or superior to that obtained by standard Id-
KLH protein vaccine. However, this protection was dependent
on the inclusion of xenogeneic Ig constant region. The ability of
recombinant adenovirus encoding a lymphoma Id gene to induce
humoral and T cell-mediated anti-Id responses was evaluated also
in the A20 murine B cell lymphoma model. A single vaccination
with an adenoviral vector encoding a scFv derived from the lym-
phoma tumor Id coupled to the human IgG1 Fc (Ad.A20hFc)
elicited a speciﬁc anti-Id antibody response and protection in
challenged animals (Armstrong et al., 2002).
Among non-replicative viruses, adeno-associated viruses
(AAV) have been extensively explored as transgene delivery vectors
for their capacity to infect mainly non-dividing cells, such as mus-
cle cells, and to induce a long-term expression of the transgene.
The potentiality of these vectors for immunotherapeutical pur-
poses has been intensely explored (Manning et al., 1997; During
et al., 1998; Liu et al., 2000; Xin et al., 2002). Overall, these studies
demonstrated the reliable capacity of recombinant AAV (rAAV)
to induce speciﬁc immunity to foreign antigens upon intramus-
cular, subcutaneous, and oral administration. In this regard, we
explored the possibility to induce anti-Id immune responses by
means of rAAV-mediated vaccinations. We demonstrated that
immunization with two recombinant vectors, encoding the BCL1
murine B cell lymphoma scFv (IdBCL1) fused to the human IgG1
CH3 domain (IdBCL1/CH3), induced signiﬁcant anti-Id anti-
body titers one month from rAAV injection (Cesco-Gaspere et al.,
2008). However, while a single intra-muscular injection of rAAV-
IdBCL1/CH3 produced efﬁcient tumor rejection in vivo, anti-Id
antibody titers were signiﬁcantly lower compared to previous
standard immunizations consisting of repetitive administration
of plasmid DNA by gene gun. Interestingly, when biolistic and
rAAV immunization were combined in a prime-boost vaccination
regimen the anti-Id immune response was further improved with
a concordant increase in tumor protection. The mechanism that
drives the efﬁcacy of the prime-boost phenomenon is not clearly
identiﬁed. In most cases, the huge amount of antigen supplied
by the recombinant virus, in this case rAAV, seems to guarantee a
more robust expansion of the antigen-speciﬁc immune response
primed by the initial vaccination with naked DNA.
TARGETING OF ANTIGEN-PRESENTING IMMUNE CELLS
Alternative ways to enhance immunogenicity of Ids have been
investigated to overcome the need of chemical cross-linking and
adjuvants that may have deleterious side effects. Among them,
immunization with autologous dendritic cells (DCs) pulsed with
the Id protein or in vivo targeting of antigen-presenting cells
(APCs) were tested. The ﬁrst approach produced encouraging
results in different clinical trials (Hsu et al., 1996; Timmerman
et al., 2002). A combination of sequential administration of pulsed
DCs andof Id-KHLprotein,was also found tobe efﬁcient in induc-
ing both humoral and cellular anti-lymphoma Id immunity (Hsu
et al., 2001). A more recent study reported the induction of protec-
tive immunity in two lines of transgenic mice by pulsing DCs with
an anti-idiotypic antibody (6D12) mimicking Her-2/neu antigen
(Saha and Chatterjee, 2010).
www.frontiersin.org November 2012 | Volume 2 | Article 159 | 5
“fonc-02-00159” — 2012/11/7 — 21:44 — page 6 — #6
López-Requena et al. Idiotypes as vaccines in cancer treatments
In an alternative setting, Id vaccines have been targeted toAPCs
by fusion with chemokines, CD40-ligand (CD40L) or antibodies
speciﬁc for APC-restricted molecules (Figure 3). In a pioneering
study, two chemokines, IP-10 andMCP-3,wereN-terminally fused
to the Ids from two different lymphoma models in the scFv for-
mat, and delivered as plasmid DNA or puriﬁed proteins (Biragyn
et al., 1999). The fusions elicited strong immune responses that
protected from tumor challenge in both models and with both
chemokines. The adjuvant effect was supposed to be due to tar-
geting of the antigen to professional APCs where the receptor for
chemokines is expressed. This view was suggested by the require-
ment of a physical link between the scFv-Id antigen and the
functionally active chemokine. Using a similar vaccine design, the
same group demonstrated that the chemokine fusion facilitates the
presentation of the tumor Id by APC via the MHC class II path-
way (Biragyn et al., 2004). Other chemokines have been exploited
as targeting unit for APC priming, such as MIP-1α and RANTES.
The presence of a xenogeneic dimerizing unit (human IgG3 CH3
domain) was found to be essential in inducing protective immune
response in mice immunized with a vaccine consisting of the
tumor Id fused to MIP-1α or RANTES chemokines (Fredriksen
and Bogen, 2007). A DNA vaccine consisting of the A20 murine B
cell lymphoma Id in scFv format fused to the MCP-3 chemokine
and administered in sites pretreated with cardiotoxin had a higher
impact on overall survival of challenged mice than the scFv alone.
The presence of the myotoxin, which recruited APCs by promot-
ing sterile inﬂammation, was also advantageous for the efﬁcacy of
the vaccination (Qin et al., 2009).
Targeting of antigen toAPCs can be achieved also by antibodies
or scFv speciﬁc for APC-restricted molecules. A DNA immunogen
encoding a bivalent tumor Id and an anti-MHC class II scFv anti-
body was able to induce in mice higher levels of anti-Id antibodies
than in control animals that had received an unrelated target-
ing unit or in animals not expressing the speciﬁc class II allele.
The immune response led to tumor protection in two murine
models, the MOPC315 myeloma and the A20 B cell lymphoma
(Fredriksen et al., 2006). It was demonstrated a superior priming
capacity of APC derived from draining lymph nodes to activate
antigen-speciﬁc T cells in vitro when animals were vaccinated with
the MHC class II-speciﬁc plasmid. Concordantly, antigen-speciﬁc
CD4+ T cells in lymph nodes were found to be more activated in
these animals, consistent with a targeting effect due to enhanced
uptake of protein by APC and presentation to CD4+ T cells. The
same prototype construct, encoding a myeloma patient-derived
Id, efﬁciently induced in mice speciﬁc anti-Id responses that were
patient-speciﬁc and dependent on the targeting effect (Froyland
et al., 2011).
CD40has been also exploited asAPC-targeting receptor. Fusion
of a chimeric antibody containing the 38C13 murine B cell lym-
phoma Id to CD40L improved immunogenicity compared to
administration of the antibody alone, to levels similar to those of
an Id/GM-CSF fusion protein (Huang et al., 2004). In vivo target-
ing of CD40+ APCs with a vaccine consisting on theA20 murine B
cell lymphoma Id chemically conjugated to an anti-CD40 antibody
induced more efﬁcient tumor protection than a classic vaccination
with Id-KLHplusGM-CSF.Monophosphoryl lipidA but notGM-
CSF had a synergistic effect with the Id conjugated to the antibody
(Carlring et al., 2012).
Recently, the 38C13 murine B cell lymphoma-derived scFv-
Id was linked, in a diabody format, to a B cell targeting moiety
constituted by an anti-CD19 scFv. The recombinant molecule was
proven to bind to non-cognate B cells, which in turn stimulated Id-
speciﬁc B cells. Animals vaccinated with this diabody developed
potent Id-speciﬁc antibody and T cell responses comparable to
FIGURE 3 | Antigen-presenting cell (APC)-targeting strategies. Antigen
is delivered to APC by antibodies speciﬁc to APC-restricted molecules or
internalizing receptors, or by APC-speciﬁc ligands. Antigen is efﬁciently
internalized, processed and presented to activate CD4+ and/or CD8+T cells.
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those induced by 38C13-KLH. Interestingly, such diabodies were
produced in a cell-free protein expression system that allowed
the preparation of proper amounts of vaccine in a few hours
(Ng et al., 2012).
ANTIBODIES VERSUS T CELL RESPONSES
The evidences accumulated so far on tumor protection induced
by anti-Id immunization do not allow to clearly deﬁne the main
mechanism involved in the rejection of tumor cells. The under-
standing of this issue is of major relevance, since this may allow
improving vaccine efﬁcacy and prognosis of lymphoma patients.
In mouse models, protein-based vaccines were shown to work
through an anti-Id antibody-dependent mechanism (Racila et al.,
1995; Timmerman and Levy, 2000) or through the induction of
effector T cells (Biragyn et al., 1999). In human studies, clinically
relevant immune responses induced by immunization with Id-
protein or Id-pulsed DCs were dependent on the induction of
Id-speciﬁc CD8+ T cells (Bendandi et al., 1999). Moreover, syn-
thetic peptides derived from Ig framework region shared among
lymphoma patients were able to induce cytotoxic responses (Tro-
jan et al., 2000). These evidences indicated that malignant B
cell can process and present class I-restricted peptides derived
from Ig framework V regions. The study of Inoges et al. (2006)
clearly reported the induction of a humoral and cytotoxic cellular
immune response against Id in lymphoma patients immunized
with KLH-coupled Id in association with GM-CSF.
Upon DNA immunization, the in vivo antigen synthesis and
processing should favor the loading of antigenic peptides onto
MHC class I molecules and the induction of cytotoxic T lym-
phocyte (CTL) responses only if the delivered DNA construct
is expressed by APCs, which depends on the method of DNA
delivery. However, by using a chimeric mouse/human IgG DNA
vaccine delivered by intramuscular injection, it was shown that
protection in the 38C13 murine B cell lymphoma model was
not impaired by CD4+/CD8+ T cell depletion (Syrengelas and
Levy, 1999).
Similarly, we demonstrated that anti-Id antibodies, were totally
essential to confer tumor protection in the BCL1 murine B cell
lymphoma model (Cesco-Gaspere et al., 2005), despite the fact
that DNA was intradermally delivered by gene gun immunization,
a method that allows expression of antigen also by dermal resident
DCs (our unpublished observations). However, since we did not
deplete any T cell subpopulation, a possible contribution of pro-
tective T cells in this model, in addition to antibodies, cannot be
completely ruled out.
On the contrary, in the 38C13 as well as in the A20 murine
B cell lymphoma models, protection was found to be depen-
dent on CD4+ and CD8+ T cells, when animals were vaccinated
with a DNA construct encoding the scFv-Id fused to two different
chemokines (Biragyn et al., 1999). In addition, cytotoxic cell lines,
with proliferative and cytotoxic activity against the A20 murine B
cell lymphoma cell line, were efﬁciently generated from mice vac-
cinated with a scFv adenoviral vaccine (Armstrong et al., 2002).
Interestingly, in some cases Id-speciﬁc CD4+ T cells have been
found to be unique players in tumor rejection. In the murine
A31 B cell lymphoma and 5T33 myeloma models, protection
induced by DNA vaccination with a scFv fused to potato X virus
protein was clearly compromised upon in vivo depletion of CD4+
T cells (Savelyeva et al., 2001). Another study performed on this
issue showed that tumor protection against B lymphoma cells was
induced in absence of B cells, antibodies and CD8+ T cells in a T
cell receptor (TCR)-transgenic mouse model speciﬁc for an MHC
class II-restricted peptide of the λ2 Ig light chain derived from the
MOPC315 plasmacytoma (Lundin et al., 2003).
Considering clinical trials, a positive correlation between anti-
Id antibody response and overall survival was found in patients
with follicular lymphoma receiving the Id-KLHplusGM-CSF vac-
cine. In contrast, theT cell responsewasnot associatedwith clinical
outcome, although this was attributed to the variability of the cel-
lular assays (Ai et al., 2009). In a trial with an Id vaccine in the Fab
format, the cellular response correlated with higher progression-
free survival in the group of patients receiving the vaccine as ﬁrst
line treatment, but not in those immunized after remission consol-
idation following chemotherapy (Navarrete et al., 2011). Previous
studies had indicated an association between T cell responses and
clinical beneﬁt (Bendandi et al., 1999; Inoges et al., 2006). In any
case, the induction of Id-speciﬁc CTLs is almost always a desired
feature. The use of GM-CSF in current clinical vaccine formu-
lations is indeed directed to achieve this goal. Several patients
enrolled in clinical trials developed T cell responses against the
immunizing Id (Mahaseth et al., 2011; Rezvani and de Lavallade,
2011). T cell speciﬁcities were mapped to peptides derived from
the CDRs of VH (Navarrete et al., 2011). Induction of VH-CDR3-
speciﬁc CTLs was also achieved when immunizing mice with a
plasmid encoding this peptide fused to tetanus toxin FrC (Iurescia
et al., 2010). In fact, DNA immunization is an excellent tool to
induce cellular responses (Stevenson et al., 2011).
Another strategy to achieve cellular responses against the
immunizing Id is vaccination with Id-pulsed DCs. In a small
trial, autologous DCs incubated with the Id and KLH and re-
administered to the patients activated T cells speciﬁc for the Id
in half of them, although the relative contribution of Th1 and
Th2 compartments in this response was not deﬁned (Rollig et al.,
2011). However, it has also been reported that immunization
with DCs pulsed with conserved idiotopes shared by different
Ids (i.e., peptides from J regions) can lead to activation of reg-
ulatory T cells and thus dampen the response against Id-speciﬁc
idiotopes such as H-CDR3 peptides (Warncke et al., 2011). In
another approach, a shift toward Id-speciﬁc Th1 response was
achieved in the A20 murine B cell lymphoma model using a
complex mixture containing: the Id DNA, MIP3-α chemokine,
and a small interfering RNA to silence IL-10. This formulation
induced CTL activation and protection after tumor challenge
(Singh et al., 2011).
Furthermore, the anti-tumor effect of the MCP-3 chemokine-
scFvDNAvaccine in combinationwith cardiotoxinwas dependent
on the cellular response, as it was abrogated after T cell depletion,
but independent of the humoral response, as protection was also
achieved in B cell-deﬁcient mice (Qin et al., 2009).
In the case of human antigen-mimicking Ab2 used in the clin-
ics, the Id is neither foreign nor strictly self, but syngeneic. It has
been suggested that for T cell responses the presence of the human
Fc could be advantageous (Durrant et al., 2001). The 105AD7
mAb, which mimics the complement regulatory protein CD55
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Table 1 | Summary of some vaccine designs to foster anti-Id immune response discussed in the text.
Id-vaccine design Target Reference
Carrier and
adjuvants
Tumor Ig coupled to KLH + GM-CSF Human lymphoma Bendandi et al. (1999), Barrios et al. (2002),
Inoges et al. (2006), Redfern et al. (2006),
Timmerman et al. (2009)




Tumor scFv fused to TT-FrC 38C13 murine B cell lymphoma Patel et al. (2011)
Tumor scFv fused to human γ1 CH3 BCL1 murine B cell lymphoma Benvenuti and Burrone (2001)
Tumor Fab + GM-CSF Human lymphoma Bertinetti et al. (2006),
Navarrete et al. (2011)
Chimeric tumor Ig fused to GM-CSF, IL-2, IL-4 38C13 murine B cell lymphoma Tao and Levy (1993), Chen et al. (1994)
DNA vaccines Tumor Id H-CDR3 fused to TT-FrC 38C13 murine B cell lymphoma Iurescia et al. (2010)
Tumor scFv fused to TT-FrC Murine A31 B cell lymphoma and
5T33 myeloma
King et al. (1998)
Tumor scFv fused to the coat protein of
Potexvirus
Murine A31 B cell lymphoma and
5T33 myeloma
Savelyeva et al. (2001)
Tumor scFv fused to human γ1 CH3 BCL-1 murine B cell lymphoma Benvenuti et al. (2000)
Tumor scFv fused to B subunit of E. coli heat
labile toxin
BCL-1 murine B cell lymphoma Chen et al. (2009)
Chimeric tumor Ig fused to GM-CSF 38C13 murine B cell lymphoma Syrengelas et al. (1996)
Viral vectors Tumor scFv fused to human γ1 CH3 in
adeno-associated virus vector
BCL-1 murine B cell lymphoma Cesco-Gaspere et al. (2008)
Chimeric tumor Ig in adenovirus vector Murine 38C13 and BCL-1 B cell
lymphomas
Timmerman et al. (2001)
APC-loading/
targeting
Tumor scFv fused to IL-1β-derived peptide 38C13 murine B cell lymphoma Hakim et al. (1996)
Tumor scFv fused to IP-10 or MCP-3 Murine 38C13 and A20 B cell
lymphomas
Biragyn et al. (1999)
Tumor scFv fused to MCP-3 + cardiotoxin A20 murine B cell lymphoma Qin et al. (2009)
Tumor scFv fused to human γ3 CH3-hinge and
to MIP-1α or RANTES
Murine A20 B cell lymphoma and
MOPC315 myeloma
Fredriksen and Bogen (2007)
Tumor scFv fused to human γ3 CH3-hinge and
to an anti-MHC class II scFv
Murine A20 B cell lymphoma and
MOPC315 myeloma
Fredriksen et al. (2006)
Tumor scFv fused to an anti-CD19 scFv
(diabody)
38C13 murine B cell lymphoma Ng et al. (2012)
Chimeric tumor Ig fused to CD40L 38C13 murine B cell lymphoma Huang et al. (2004)
Tumor Ig chemically conjugated to an
anti-CD40 antibody
A20 murine B cell lymphoma Carlring et al. (2012)
Tumor Ig-loaded DCs Human lymphoma Hsu et al. (1996),
Timmerman et al. (2002)
Id, idiotype; Ig, immunoglobulin; KLH, keyhole limpet hemocyanin; GM-CSF, granulocytemacrophage–colony stimulating factor; CpG, oligodeoxynucleotides containing
unmethylated CG dinucleotides; IFN-α, interferon alpha; scFv, single-chain variable fragment;TT-FrC, tetanus toxin fragment C; IL-2, interleukin 2; IL-4, interleukin 4; Fab,
antigen binding fragment; H-CDR3, heavy chain complementary-determining region 3; IL-1β, interleukin 1 beta; IP-10, interferon inducible protein 10; MCP-3, monocyte
chemotactic protein 3; MIP-α, macrophage inﬂammatory protein 1 alpha; RANTES, regulated and normal T cell expressed and secreted; CD40L, CD40-ligand; DCs,
dendritic cells; MHC, major histocompatibility complex.
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(Spendlove et al., 2000) was obtained by the heterohybridoma
technique using lymphocytes from a colorectal cancer patient
administered, for diagnostic purposes, with an anti-tumor mouse
mAb (Austin et al., 1989). Vaccination of colorectal (Robins et al.,
1991; Ullenhag et al., 2006) and osteosarcoma (Pritchard-Jones
et al., 2005; Ullenhag et al., 2008) patients with 105AD7 mAb in
alum alone or with BCG in the ﬁrst immunization (Ullenhag
et al., 2006), either failed to induce an anti-anti-idiotypic antibody
response (Robins et al., 1991; Ullenhag et al., 2006) or induced a
weak response against CD55 (Pritchard-Jones et al., 2005), but it
was able to activate both anti-Ab2 and anti-CD55 T cell responses
(Ullenhag et al., 2006, 2008).
In one study B lymphocytes from a patient with colorectal
cancer treated with a mouse mAb, speciﬁc for the epithelial-cell
adhesion molecule (Ep-CAM), were immortalized with Epstein–
Barr virus to isolate anti-idiotypic antibodies (Steinitz et al., 1988).
A pool of these Ab2, given in alum either unconjugated or conju-
gated to immunogenic peptides from the Bordetella pertussis toxin
subunit S1, induced humoral and cellular responses against the
antibodies and the Ep-CAM antigen (Fagerberg et al., 1995). In
another study immunization with the antigen or the Ab2 mAb
with GM-CSF as adjuvant was compared. While both immuno-
gens generated speciﬁc T cell responses, the Ab2 mAb did not
induce anti-Ep-CAM antibodies (Mosolits et al., 2004b). The
induction of antigen-speciﬁc T cell responses was later conﬁrmed
in a trial where the recombinant antigen, the Ab2 mAb and a
combination of both, also with GM-CSF, were tested (Mosolits
et al., 2005). Interestingly, in a preclinical study with Ep-CAM-
expressing transgenic mice, the Ab2 protein vaccine was more
efﬁcient than the Ab2 DNA vaccine for the anti-anti-idiotypic
antibody response. In the genetic strategy, fusion to GM-CSF but
not the presence of a xenogeneic Fc region, enhanced the antibody
response against the Ab2 (Mosolits et al., 2004a).
CONCLUSION
Although the Id of Igs is nominally a self-antigen and conse-
quently poorly immunogenic, strategies intended to induce anti-Id
immune responses have successfully demonstrated the feasibil-
ity of breaking tolerance against Ids, both in animal models and
in the human context. The employment of adjuvants, carriers,
viral vectors, or the direct recruitment of immune-related cells has
allowed translating Id targeting by the immune system into thera-
peutic approaches for Ig-expressing tumors (Table 1). Treatment
of several other malignancies can also involve Id-based vaccina-
tion, taking advantage of antigen mimicry by Ids. Solid evidences
of clinical beneﬁt are however still awaited, and more work is
needed to unveil the mechanisms and factors that impact on the
generation of therapeutic anti-Id immune responses.
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